2008
Advances in Adjuvant Endocrine Therapy for Postmenopausal Women
Lin NU, Winer EP. Advances in Adjuvant Endocrine Therapy for Postmenopausal Women. Journal Of Clinical Oncology 2008, 26: 798-805. PMID: 18258989, DOI: 10.1200/jco.2007.15.0946.Peer-Reviewed Original ResearchConceptsPostmenopausal womenAromatase inhibitorsEndocrine therapyBreast cancerHormone receptor-positive breast cancerHormone receptor-positive cancersInitial breast cancer diagnosisReceptor-positive breast cancerMost postmenopausal womenUpfront aromatase inhibitorsYears of tamoxifenAdjuvant endocrine therapyDisease-free survivalReceptor-positive cancersCommon tumor subtypeBreast cancer diagnosisPostmenopausal settingEndocrine treatmentOverall survivalDisease recurrenceRandomized trialsAvailable trialsIndividual patientsHigh riskTumor subtypes
2003
The aromatase inhibitors as adjuvant therapy for hormone receptor-positive breast cancer.
Ligibel JA, Winer EP. The aromatase inhibitors as adjuvant therapy for hormone receptor-positive breast cancer. Journal Of The National Comprehensive Cancer Network 2003, 1: 215-21. PMID: 19768880, DOI: 10.6004/jnccn.2003.0020.Peer-Reviewed Original ResearchConceptsHormone receptor-positive breast cancerReceptor-positive breast cancerAdjuvant hormonal therapyAromatase inhibitorsAdjuvant settingBreast cancerATAC trialHormonal therapyThird-generation aromatase inhibitor anastrozoleMost postmenopausal womenNew hormonal agentsAromatase inhibitor anastrozoleEarly breast cancerMetastatic breast cancerUse of tamoxifenRelapse-free survivalBreast cancer recurrenceAdjuvant therapyPostmenopausal patientsPostmenopausal womenThromboembolic eventsOverall mortalityHormonal agentsPatient populationUterine cancer